Aldosterone and the vascular system

被引:61
作者
Cachofeiro, Victoria [1 ]
Miana, Maria [1 ]
de las Heras, Natalia [1 ]
Martin-Fernandez, Beatriz [1 ]
Ballesteros, Sandra [1 ]
Fernandez-Tresguerres, Jessus [1 ]
Lahera, Vicente [1 ]
机构
[1] Univ Complutense, Dept Fisiol, Fac Med, Sch Med, E-28040 Madrid, Spain
关键词
aldosterone; inflammation; endothelial function; vascular remodeling;
D O I
10.1016/j.jsbmb.2008.03.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aldosterone can act in different tissues exerting physiological and pathological effects. At the vascular level, aldosterone affects endothelial function since administration of aldosterone impaired endothelium-dependent relaxations. in addition, the administration of mineralocorticoid receptor antagonists ameliorate relaxation to acetylcholine in models of both hypertension and atherosclerosis and in patients with heart failure. A reduction in nitric oxide levels seems to be the main mechanism underlying this effect due to a reduction in its production as well as an increase in its degradation by reactive oxygen species. Aldosterone is a pro-inflammatory factor that can participate in the vascular inflammatory process associated with different pathologies including hypertension through activation of the NF kappa B system, which mediates the vascular production of different cytokines. This mineralocorticoid also participates in the vascular remodeling observed in hypertensive rats since the administration of eplerenone improved the media-to-lumen ratio in these animals. This effect seems to be due to an increase in extracellular matrix. In summary, aldosterone through mineralocorticoid receptors can participate in the vascular damage associated with different pathologies including hypertension through its prooxidant, pro-inflammatory and profibrotic effects that triggered endothelial dysfunction, an inflammatory process and vascular remodeling. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:331 / 335
页数:5
相关论文
共 66 条
  • [1] Do human vascular endothelial cells produce aldosterone?
    Ahmad, N
    Romero, DG
    Gomez-Sanchez, EP
    Gomez-Sanchez, CE
    [J]. ENDOCRINOLOGY, 2004, 145 (08) : 3626 - 3629
  • [2] Aldosteronism and peripheral blood mononuclear cell activation - A neuroendocrine-immune interface
    Ahokas, RA
    Warrington, KJ
    Gerling, IC
    Sun, Y
    Wodi, LA
    Herring, PA
    Lu, L
    Bhattacharya, SK
    Postlethwaite, AE
    Weber, KT
    [J]. CIRCULATION RESEARCH, 2003, 93 (10) : E124 - E135
  • [3] Aldosterone modulates neural vasomotor response in hypertension:: role of calcitonin gene-related peptide
    Balfagón, G
    Márquez-Rodas, I
    Alvarez, Y
    Alonso, MJ
    Cachofeiro, V
    Salaices, M
    Lahera, V
    [J]. REGULATORY PEPTIDES, 2004, 120 (1-3) : 253 - 260
  • [4] Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats
    Blanco-Rivero, J
    Cachofeiro, V
    Lahera, V
    Aras-Lopez, R
    Márquez-Rodas, I
    Salaices, M
    Xavier, FE
    Ferrer, M
    Balfagón, G
    [J]. HYPERTENSION, 2005, 46 (01) : 107 - 112
  • [5] c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats
    Callera, GE
    Montezano, ACI
    Yogi, A
    Tostes, RC
    He, Y
    Schiffrin, EL
    Touyz, RM
    [J]. HYPERTENSION, 2005, 46 (04) : 1032 - 1038
  • [6] Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes
    Davies, JI
    Band, M
    Morris, A
    Struthers, AD
    [J]. DIABETOLOGIA, 2004, 47 (10) : 1687 - 1694
  • [7] Nuclear factor κB signaling in atherogenesis
    de Winther, MPJ
    Kanters, E
    Kraal, G
    Hofker, MH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : 904 - 914
  • [8] Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift
    Epstein, M
    [J]. JOURNAL OF HYPERTENSION, 2001, 19 (05) : 829 - 842
  • [9] Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
    Farquharson, CAJ
    Struthers, AD
    [J]. CIRCULATION, 2000, 101 (06) : 594 - 597
  • [10] Aldosterone induces acute endothelial dysfunction in vivo in humans:: evidence for an aldosterone-induced vasculopathy
    Farquharson, CAJ
    Struthers, AD
    [J]. CLINICAL SCIENCE, 2002, 103 (04) : 425 - 431